Figure 3Decrease in α-ketoglutarate dehydrogenase (AKGDm) activity, associated with Alzheimer’s disease (AD), shows cell-type and regional effects in silico consistent with experimental data
Kernel density plots show the distribution of feasible fluxes for various reactions (a–e). An in silico reduction of AKGDm flux from normal activity (a–e, solid lines) to AD brain activity (a–e, dashed) decreases (a) the oxidative metabolic rate for glutamateric and cholinergic neurons, but not GABAergic neurons. This results from a decrease in the feasible fluxes for oxidative phosphorylation (e.g., cytochrome c oxidase) for both (b) glutamatergic and (c) cholinergic neurons, but not (d) GABAergic cells. This cell-type-specific protection from the AKGDm deficiency results from (e) an increased flux through the GABA shunt in GABAergic cells, by bypassing the damaged AKGDm (f). GABAergic cells maintain a higher GABA shunt flux because of the expression of glutamate decarboxylase (GAD). Neuroprotective properties of GAD are supported by gene expression. (g) Severely damaged brain regions in AD patients have lower GADNMN expression in control brain, while high GADNMN regions (SFG and VCX) show little damage. In AD brain, (h) severely affected regions (HIP and EC) show an increase in GADNMN and the GAD-inducing DLX family, suggesting that non-GAD expressing neurons may be lost in AD. EC = entorhinal cortex, HIP = hippocampus, MTG = middle temporal gyrus, PC = posterior cingulate cortex, SFG = superior frontal gyrus, VCX = visual cortex, NMN = neuron marker normalized, inhib = inhibited. All reaction and metabolite abbreviations are defined in Supplementary Tables 1– 2.